Brian Taylor’s Post

Discover how Lifebit is driving efficiency in drug discovery with our latest module. By harnessing external expertise and cutting-edge technologies, we're working to accelerate the path to novel therapeutics. Explore the insights in our latest white paper: https://bit.ly/3w7mQOU #DrugDiscoveryWorkflows #Pharma #Lifebit

Our SPATIALPlex Solutions bring innovative approaches to your biomarker and clinical development programs. Spatially visualizing drug activity with unparalleled precision, Flagship Biosciences supports discovery and target engagement decisions that transcend conventional approaches and enable vivid insights to refine drug efficacy. Learn more… https://hubs.la/Q02rq17H0 #SpatialBiology #SpatialPlexSolutions #DigitalPathology #DrugDevelopment

Reflecting on a successful first day at the 42nd JPM Healthcare Conference with GenScript, GenScript ProBio, and Legend Biotech!   Ying Huang, CEO of Legend Biotech, shared the positive strides and future outlook of Legend Biotech's cell therapy research and development pipeline.   Looking ahead to day two, Li Chen, CEO of GenScript Probio, will present on January 10, exploring Probio's strengths in drug discovery and the CDMO field.   We will also host the GenScript Biotech Global Forum 2024, bringing together leaders from academia, regulatory agencies, enterprises, and the capital market to explore the future development of these therapies and build a platform for mutual exchange and cooperation.   Stay tuned for updates as we navigate the forefront of biotech innovation at the JPM Healthcare Conference!   Find more details here: https://lnkd.in/eVuenHDT #biotechnology #lifesciences #genetherapy #celltherapy #biotechindustry #GSforum2024

It’s not often that a reporter takes the time to ask about what drives your team to innovate and why at Juvena we decided to focus on secreted proteins. We are grateful to David Wild for the opportunity to reflect on how our CEO Dr. Hanadie Yousef's interests in biopharma innovation are shaping our approach to developing regenerative therapeutics for chronic and rare conditions. If you want to learn more about why we’re so excited to advance our pipeline and partner with large pharma to solve some of the greatest unmet needs of our time, check out the article linked below (subscription required). Here’s an excerpt from the article: "Juvena Therapeutics employs advanced computing to map the 4,000 proteins secreted by human cells. Through an AI-enabled platform, the company can identify potential protein-disease relationships and engineer medicines accordingly. By integrating AI, robotics and other cutting-edge technologies, Juvena accelerates preclinical screening and advances promising candidates to in-house clinical development. The platform has already generated an asset ready for clinical trials for Myotonic Dystrophy, a preclinical asset in obesity, and over 50 promising leads." #womeninbiotech #womeninlifescience #longevity https://lnkd.in/gnk7QaBd

Yesterday, I attended a webinar delivered by Kim Watanabe, Michele Duggan, and Mindy Sadik from Thermo Fisher Scientific, which focused on positioning early cell therapy programs for clinical success. The session provided insights into mitigating risks and ensuring GMP readiness in this rapidly evolving field. Key takeaways from the webinar included: 1. Strategic Planning: It is essential to 'begin with the end in mind', strategically planning every step to mitigate risks and ensure GMP readiness. 2. Technological Integration: Streamlining workflows through the integration of advanced technologies can significantly enhance efficiency. 3. Operational Optimisation: Efficiency can be optimized through various means, such as automation, digitisation, and scalable platforms. 4. Analytical Rigor: Analytical assays play a critical role and should be qualifiable, transferable, and adhere to appropriate standards and controls. 5. Collaborative Partnerships: Collaborating with CRO/CDMO partners simplifies the cell therapy value chain and enhances patient-centricity. Reflecting on the insights shared, it's evident that many of these principles resonate with our approach at adthera bio. We've embraced a digital-first mindset and integrated a diverse range of automated platforms, including closed systems. Our goal at adthera bio is to bring novel C&GTs to the market with a highly personalised approach, ensuring a seamless journey from the client to the patient. #cellandgenetherapy #atmps #digitalfirst #cell&genetherapyinsights #biotechnology

#ClinicalTrial #DrugDevelopment #Biotech Clinical trial complexity continues to grow, especially when it comes to biomarker studies and the early phases of research. Overcoming challenges like coordinating study setup, sample logistics, and timely result delivery are key to reaching study milestones and progressing to the next phase. Discover how LabConnect’s FSP team accelerates clinical trials with flow cytometry expertise and insights into the biological activity of investigational therapies. 👉 https://lnkd.in/gzjAUJKB

As any scientist will know, our basic tools are pipettes. Its something that scientists get very attached to, and everyone has their favourites!! We love the INTEGRA Biosciences pipettes and when we won a startup prize, we were ecstatic. They are so easy to use, tips fit snug and importantly we have separated our workflows with different set of pipettes really limiting our cross contamination. Enabling us to work swiftly, and really helping us progress. #antibodytherapeutics #antibodydiscovery #curecancer #startup

Join our upcoming Bench Tip webinar that explores the creation and application of 3D cellular models for studying disease pathways and enhancing drug development. Gain insights from the experts on model design, validation, and overcoming various challenges.  #3DCellModels #DrugDevelopment #CellularBiology https://lnkd.in/gcMZD4dd

Today's #biotechnews gives us a peek at what's coming next in medicine. Roche just spent a lot of money scooping up two smaller companies with promising new drugs. One deal could lead to better options for #breastcancerpatients when current meds stop working, while the other could help improve eye treatments for people with vision problems. Targeting specific health issues like this can often help lead to breakthroughs for #biotech companies—and potential investment opportunities for the rest of us! https://loom.ly/jQc4NcY

Now Released: The Exosome Characterization & Analytical Development Summit Agenda! Coming to Boston on April 23-25, this unmissable summit will hear from the pioneers of exosome analytics to provide solutions to the key challenges facing the field. It offers a comprehensive forum, equipping you with the skills needed to establish robust techniques, select the best instruments, ensure quality, and seamlessly navigate regulatory processes. What to Expect: 🔍 In-depth technical content of exosome analysis and parameters for confidence in quality. 📊 Defining standardized tools and techniques while keeping regulatory guidance in mind for clinical progression. 🤝 Bridging communications and networking between Analytical Experts and Decision Makers. Don't miss out, join us to stay ahead of emerging clinical developments and meet pioneers in the field to propel exosome therapeutics' potential! Want to learn more? Download the full event guide: https://ter.li/oux4n4 Visit the website: https://ter.li/ymgvli Secure your ticket: https://ter.li/qxgem8 #Exosomes #ExtracellularVesicles #ExosomeCharacterization #EV #ExosomeAnalytics #ExosomeTherapeutics